Researchers aim AI at rising oral cancers with $3.3M grant from National Cancer Institute

On January 5, 2021 Researchers at Case Western Reserve University and partners in the United States and India reported that are applying the investigative and predictive capabilities of artificial intelligence (AI) to help physicians customize treatments for patients with oral squamous cell carcinomas (Press release, Case Western Reserve University, JAN 5, 2021, View Source [SID1234573758]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Research shows that oral squamous cell carcinomas is already the 8th most common cancer type worldwide and numbers are steadily increasing in the United States, India and other parts of Asia.

The National Cancer Institute awarded a five-year, $3.3 million grant to a group led by Anant Madabhushi, the Donnell Institute Professor of Biomedical Engineering at Case Western Reserve and head of the Center for Computational Imaging and Personalized Diagnostics (CCIPD), and James Lewis Jr., a Professor of Pathology, Microbiology and Immunology at Vanderbilt University Medical Center.

The CCIPD has become a global leader in AI-driven precision medicine research. Madabhushi and his research team at the CCIPD hold more than 60 patents, many tied to their work in various cancers.

In this work, researchers will use advanced computer vision and machine learning techniques to identify cancer and immune cells on digitized images of oral squamous cell carcinoma tissue slides and then recognize spatial patterns among those cells.

This technology allows computerized vision to recognize patterns and quantify features that simply are beyond the human visual system but are powerful indicators of tumor biology. These algorithms will help oncologists and pathologists to then better determine which cancers are more versus less aggressive.

This, in turn, will then enable them to identify which patients with early stage disease could safely receive surgery alone, versus who might need postoperative radiation. In addition, it could help identify which patients with advanced stage disease might need chemotherapy with radiation after initial treatment versus who may be adequately treated with radiation alone.

Madabhushi and Lewis will work with a number of partners–Cleveland Clinic and University Hospitals in Cleveland, the San Francisco VA Health System, and Tata Memorial Centre in Mumbai, India–in a national and global endeavor to improve oral cavity squamous cell carcinoma patient care with advanced technology and data sharing.

The clinical partners will provide glass slides to be digitized or will directly provide digitally scanned whole slide images which will be used to train the AI algorithms for predicting outcomes as well as treatment benefit.

The team will also have access unique datasets from completed prospective, randomized, clinical trials of oral squamous cell carcinoma patients at the Tata Memorial Center as well as from the cancer clinical cooperative group NRG Oncology. The datasets that will allow for validation of the AI tools.

Seeking precise, personal predictions

Currently, physicians place oral carcinoma patients into one of three categories: those who require just surgery; those who should have surgery plus radiation therapy; or those who will need surgery, followed by radiation and chemotherapy.

"That’s the gold standard right now: a system that puts patients in those very broad categories," Madabhushi said. "For clinicians and pathologists, this is limiting because it relies on a limited number of parameters. But our machines are looking at the appearance of cells, their spatial architecture and interplay between different cell types, to parse out those patients who should actually be in another category."

For example, Madabhushi said, their AI research has already shown that there is a subset of early stage patients now placed in the first category–surgery alone–who are actually at a much higher risk and would do poorly with surgery alone.

"Instead, they should be offered radiation therapy as well, but under the current parameters, that is not called for," Madabhushi said.

The group will also look at anticipated differences in the appearance of oral cancer among patients of different races, a fast-developing aspect of Madabhushi’s AI-based investigations.

Previous research by the lab used AI to reveal apparent tissue level cellular distinctions between Black and white men with prostate cancer, enabling the development of population-specific risk prediction models.

Oral cancers rising

Oral carcinomas include cancers of the mouth, tongue, gums, and lips. According to the National Institutes of Health (NIH), these cancers can develop on the mobile tongue, the tissue lining the gums and hard palate, and on the underside of the tongue and floor of the mouth,

Oral carcinoma accounts for roughly 3% of all cancers diagnosed annually in the United States, with nearly 400,000 new cases being diagnosed annually worldwide.

Oral carcinoma most often occurs in people over age 40 and affects more than twice as many men as women. Most oral cancers are related to tobacco use, alcohol use, or both. Infection by the human papillomavirus (HPV), which is very common in oropharyngeal carcinomas, is a less common cause of oral carcinomas.

Other members of the research team include: Drs. Shlomo Koyfman, David Adelstein, and Deborah Chute at the Taussig Cancer Center, Cleveland Clinic; Dr. Ted Teknos, president of Seidman Cancer Center, University Hospitals; Dr. Stephen Connelly, San Francisco VA Health System; and Drs Sarbani Ghosh-Laskar and Swapnil Rane, Tata Cancer Center.

Case Western Reserve University is one of the country’s leading private research institutions. Located in Cleveland, we offer a unique combination of forward-thinking educational opportunities in an inspiring cultural setting. Our leading-edge faculty engage in teaching and research in a collaborative, hands-on environment. Our nationally recognized programs include arts and sciences, dental medicine, engineering, law, management, medicine, nursing and social work. About 5,100 undergraduate and 6,200 graduate students comprise our student body. Visit case.edu to see how Case Western Reserve thinks beyond the possible.

Labcorp Is Scheduled to Virtually Participate at the 39th Annual J.P. Morgan Healthcare Conference

On January 5, 2021 Labcorp (NYSE: LH), a leading global life sciences company, reported that members of the executive management team will participate in a virtual fireside chat at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 12 at 8:20 a.m. (EST) (Press release, LabCorp, JAN 5, 2021, View Source [SID1234573464]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the fireside chat will be available via the Company website at www.Labcorp.com and archived for replay.

Exact Sciences Completes Acquisition of Thrive Earlier Detection, Creating a Leader in Blood-Based, Multi-Cancer Screening

On January 5, 2021 Exact Sciences Corp. (Nasdaq: EXAS) reported that it has completed its previously announced acquisition of Thrive Earlier Detection Corp. ("Thrive") (Press release, Exact Sciences, JAN 5, 2021, View Source [SID1234573482]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Bringing Thrive into the Exact Sciences family marks a giant leap toward blood-based, multi-cancer screening becoming a reality and eventually the standard of care," said Kevin Conroy, chairman and CEO of Exact Sciences. "Today is an important one in Exact’s history as we continue to lead cancer diagnostics and transform the future for millions of patients through earlier detection and treatment guidance. On behalf of everyone at Exact Sciences, I’d like to welcome the talented Thrive team and express my excitement for the future of our company."

Oncternal Therapeutics to Participate in Fireside Chat at H.C. Wainwright BioConnect 2021 Conference

On January 5, 2021 Oncternal Therapeutics (Nasdaq: ONCT), reported that James Breitmeyer, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat hosted by H.C. Wainwright on Monday, January 11, 2021 (Press release, Oncternal Therapeutics, JAN 5, 2021, View Source [SID1234573499]). The discussion may cover Oncternal’s recent progress, upcoming catalysts, and plans for 2021. Please see additional details below:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

H.C. Wainwright BioConnect 2021 Conference (Virtual)

Title: Oncternal Therapeutics (ONCT) Fireside Chat
Date: Monday, January 11th 2021
Time: On-demand starting at 6am EST
Presenter: James Breitmeyer, President & CEO

Webcasting Link:

Click Here
Replay Link:
A replay will be accessible on the Events & Presentations page of the Investors section on the Company’s website at View Source

Nektar Appoints Dr. Brian Kotzin as Interim Chief Medical Officer and Head of Development

On January 5, 2021 Nektar Therapeutics (NASDAQ: NKTR) reported that it has appointed Brian Kotzin, MD as Interim Chief Medical Officer, Head of Development effective immediately (Press release, Nektar Therapeutics, JAN 5, 2021, View Source [SID1234573515]). Since 2017, Dr. Kotzin has served as Senior Vice President, Clinical Development and Head of Immunology at Nektar. Wei Lin will be leaving the company to pursue another opportunity.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are pleased that Dr. Kotzin will take on this key role on our development team at Nektar," said Jonathan Zalevsky, Chief R&D Officer of Nektar Therapeutics. "Since he joined Nektar in 2017, Dr. Kotzin has demonstrated strong leadership and strategic insight. He has extensive development experience and over 30 years of expertise in immunology and his strategic guidance will be invaluable to Nektar as we continue to execute on development activities for our immune-oncology and immunology pipeline."

Brian Kotzin, MD added, "I am honored to expand my role at Nektar and work alongside Dr. Zalevsky. This is an exciting time for the company with multiple registrational studies underway in a range of tumor types for BEMPEG, a broadening clinical program for NKTR-358 in a number of auto-immune disorders, and an emerging opportunity for NKTR-255 in both hematological malignancies and solid tumors."

While at Nektar, Dr. Kotzin has spearheaded the NKTR-358 development program partnered with Eli Lilly & Co. and he has also served as a development program lead for early development of NKTR-255 and NKTR-262. Dr. Kotzin was previously at Amgen for 11 years, where he served as Vice President, Global Clinical Development and Head of the Inflammation Therapeutic area directing the global development efforts for Amgen product candidates, including all immunology programs. During his tenure at Amgen, he also served as Vice President of Translational Sciences and Head of Medical Sciences/Early Development, where he was responsible for the planning and execution of early-phase clinical development in all therapeutic areas as well as the discovery and implementation of pharmacodynamic biomarkers and clinical immunology support for clinical studies. Prior to joining Amgen, Dr. Kotzin served as Head of Clinical Immunology in the Department of Medicine and as director of the Autoimmunity Center of Excellence at the University of Colorado Health Sciences Center in Denver. He previously held the position of Professor in the Departments of Medicine, Pediatrics, and Immunology at the National Jewish Medical and Research Center in Denver. In addition to academic posts in rheumatology and microbiology/immunology, Dr. Kotzin served at the Veterans Administration Medical Center in Denver as chief of the Rheumatology Section. Dr. Kotzin received a B.S. in mathematics from the University of Southern California and an M.D. from Stanford University School of Medicine. He completed a residency in internal medicine and a fellowship in rheumatology and medicine at Beth Israel Hospital in Boston. He was also a postdoctoral fellow in the Division of Immunology and Rheumatology at Stanford University School of Medicine. He is board certified in rheumatology and internal medicine.

"Over the past two years, Wei has played a leadership role in recruiting an experienced clinical development organization and executing a late-stage clinical development strategy for BEMPEG, positioning it for future success. I would like to thank him for his contributions to Nektar, and wish him the best in his next opportunity," continued Zalevsky.